575504-23-3

Basic information

• Product Name: 1H-Inden-4-ol, 5-bromo-2,3-dihydro-
• CAS NO: 575504-23-3
• Molecular Formula: C9H9BrO
• Mol File: 575504-23-3.mol

Chemical Properties

• CAS DataBase Reference: 1H-Inden-4-ol, 5-bromo-2,3-dihydro-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Inden-4-ol, 5-bromo-2,3-dihydro-(575504-23-3)
• EPA Substance Registry System: 1H-Inden-4-ol, 5-bromo-2,3-dihydro-(575504-23-3)

Safety Data

• Hazardous Substances Data: 575504-23-3(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
1H-Inden-4-ol, 5-bromo-2,3-dihydrois used as a building block in organic synthesis for the creation of more complex organic compounds. Its unique structure allows for various chemical reactions, enabling the development of novel molecules with potential applications in different fields.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 1H-Inden-4-ol, 5-bromo-2,3-dihydrois employed as a key intermediate in the synthesis of new drugs. Its potential biological activity and versatile structure make it a valuable tool for researchers working on the discovery and development of innovative therapeutic agents.
Used in Medicinal Chemistry:
1H-Inden-4-ol, 5-bromo-2,3-dihydrois utilized in medicinal chemistry for the design and optimization of drug candidates. Its unique structural features and potential biological activity contribute to the development of new compounds with improved pharmacological properties and therapeutic efficacy.
Used in Drug Discovery:
In the field of drug discovery, 1H-Inden-4-ol, 5-bromo-2,3-dihydroserves as a valuable starting point for the identification and optimization of new drug candidates. Its unique structure and properties facilitate the exploration of novel chemical space, leading to the discovery of promising therapeutic agents with potential applications in various diseases and conditions.

Upstream product

• 1641-41-4 4-indanol 

Downstream Products

• 2676863-61-7 7-(benzyloxy)-2,4,5,6-tetrahydro-1H-cyclobuta[f]inden-1-one 
• 2676863-60-6 4-(benzyloxy)-5-bromo-2,3-dihydro-1H-indene 
• 575503-46-7 ethyl N-[6-bromo-7-(4-hydroxy-3-isopropylphenoxy)indan-4-yl]malonamate 
• 1380075-78-4 ethyl N-[6-bromo-7-(4-benzyloxy-3-isopropylphenoxy)indan-4-yl]malonamate 
• 575504-93-7 7-(4-benzyloxy-3-isopropylphenoxy)-6-bromoindan-4-ylamine 

Relevant articles and documents

SULFONIMIDAMIDE COMPOUNDS AS NLRP3 MODULATORS

Described herein are compounds of Formula (I), Formula (I-A), and Formula (I-B), solvates thereof, tautomers thereof, and pharmaceutically acceptable salts of the foregoing, Further described herein are methods of inhibiting NLRP3 using said compounds, and methods of and compositions useful in treating NLRP3-dependent disorders.

Discovery of novel indane derivatives as liver-selective thyroid hormone receptor β (TRβ) agonists for the treatment of dyslipidemia

Thyromimetics that specifically target TRβ have been shown to reduce plasma cholesterol levels and avoid atherosclerosis through the promotion of reverse cholesterol transport in an animal model. We designed novel thyromimetics with high receptor (TRβ) and organ (liver) selectivity based on the structure of eprotirome (3) and molecular modeling. We found that indane derivatives are potent and dual-selective thyromimetics expected to avoid hypothyroidism in some tissues as well as heart toxicity. KTA-439 (29), a representative indane derivative, showed the same high human TRβ selectivity in a binding assay as 3 and higher liver selectivity than 3 in a cholesterol-fed rat model.

Novel Compounds

The present invention discloses a novel thyroid like compounds of formula (I), wherein R1 R2, R3, R4 and Z are as defined in the specification, method for its preparation, composition containing such compounds and use of such compounds and composition as medicament. Further, compounds of formula (I) has significantly low binding affinity to thyroid receptors and thus considerably devoid of thyrotoxic effects. The invention also relates to the use of the compound of formula (I) for the preparation of a medicament for treating various disease conditions such as obesity, dyslipidemia, metabolic syndrome and co-morbidities associated with metabolic syndrome.

NOVEL THYROID HORMONE RECEPTOR LIGAND, MEDICINAL COMPOSITIONS CONTAINING THE SAME AND USE THEREOF

The present invention provides a compound represented by general formula (I): . or pharmaceutically acceptable salts thereof, wherein W is O, S(O)m, CH2 and the like: R1 is halogen, lower alkyl, halo-lower alkyl, CN and th